The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

Takeuchi, Akihiko; Tsuchiya, Hiroyuki; Niu, Xiaohui; Ueda, Takafumi; Jeon, Dae‐Geun; Wang, Edward H. M.; Asavamongkolkul, Apichat; Kusuzaki, Katsuyuki; Sakayama, Kenshi; Kang, Yong-Koo

doi:10.1007/s00776-011-0030-x

Cited by 42 publications

(51 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a previous report of the Eastern Asian Musculoskeletal Oncology Group, the median interval between initial surgery and the first recurrence of the new cases was 16 months. The mean interval between the surgeries in the recurrent cases was 14.1 months for the repeated recurrent groups and 28.3 months for the single recurrent group [21]. Thus, all patients in this study were followed up for at least 36 months, ranging between 40 and 50 months with an average follow up of 42.4 months.…”

Section: Discussionmentioning

confidence: 99%

“…Minimizing tumor recurrence rate was our goal because the higher the recurrence rate of the tumor, the poorer outcome of the treatment has been reported [21]. By the use of this test, the post-test probability was significantly enhanced, Table 3.…”

Section: Discussionmentioning

confidence: 99%

“…Recurrencerates between 6% and 16% after wide resection and 18% and 56% after extended intra-lesional curettage and local treatment have been reported [17]- [20]. Only early local recurrence rate was found to relate with the aggressiveness of this tumor [21]. To provide a better prediction of the recurrent rate at pre-operative stage, Hsp70 expression has been explored through tumor tissues.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application

Asavamongkokul¹,

Chotiyarnwonga²,

Tirawanchai³

et al. 2015

View full text Add to dashboard Cite

Objective: To provide a better prognosis after the treatment of giant cell tumor of bone which is a common benign aggressive bone tumor by the use of thermoablation, Hsp70 expression of the tumor was explored and the relationship between the relative amount of expression of this protein and tumor recurrence was studied. Methods: Avascular parts of tumor tissues were collected from 11 patients, 3 male and 8 female with an average age of 32.27 years and were sent for the analysis of protein contents by the use of Western blot. A comparative protein analysis was used for the detection of Hsp70 and beta-actin. Monoclonal antibody was used for the identification of Hsp70. The measurement was carried out two times in one patient. The relationship between ratios of Hsp70/beta-actin and tumor recurrence during 3-year follow-up was carried out. Results: Tumor recurrence was found in 4 patients, 36.6% and none had lung metastasis. Significant HSP expression was found in all specimens. No patient with the ratio of HSP70/beta-actin expression lower than 0.66 had tumor recurrence. Sensitivity of the test was 75% and specificity was 100%. Conclusion: Expression of Hsp70 was found in giant cell tumor of bone and high relative expression of this protein related to tumor recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application

Asavamongkokul¹,

Chotiyarnwonga²,

Tirawanchai³

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Approximately 2% of patients with grade-II or recurrent lesions develop lung metastasis after a mean of 3 (range, 1-10) years. 3,4 For grade-III lesions, resection and reconstruction is recommended; chemotherapy alone is ineffective. High-dose (>40 G) radiation therapy is effective, but about 2% of radiated GCTs become malignant.…”

Section: Introductionmentioning

confidence: 99%

“…High-dose (>40 G) radiation therapy is effective, but about 2% of radiated GCTs become malignant. 4,5 Treatment options depend on the stage and location of the tumour and the age of the patient. Radical surgery is recommended, as local recurrence is common after conservative surgery (such as simple curettage and bone grafting).…”

Section: Introductionmentioning

confidence: 99%

Treating Giant Cell Tumours with Curettage, Electrocautery, Burring, Phenol Irrigation, and Cementation

Moon

Kim

Moon

et al. 2013

J Orthop Surg (Hong Kong)

View full text Add to dashboard Cite

purpose. To report on 23 patients with giant cell tumour (GCT) of the femur or tibia treated with curettage, electrocautery, burring, phenol irrigation, and cementation. Methods. Records of these 14 men and 9 women aged 22 to 38 (mean, 31) years were reviewed. The most common site involved was the distal femur (n=13), followed by proximal tibia (n=8), proximal femur (n=1), and distal tibia (n=1). The lesions were classified as grade I (n=3), grade II (n=18), and grade III (n=2). Based on histology, the tumour stage was classified as grade I (n=5) and grade II (n=18). Two of these patients had recurrences, which were initially treated with simple curettage and bone grafting of the distal femur and distal tibia. results. The mean follow-up period was 5.7 (range, 2.5-10.1) years. 14 of the 23 patients were followed up for over 10 years. No patient developed any local recurrence, remote metastasis, or complication related to surgery or adjuvant therapy.Treating giant cell tumours with curettage, electrocautery, burring, phenol irrigation, and cementation conclusion. Combined treatment entailing curettage, electrocautery, burring, phenol irrigation, and cementation was effective in treating GCT of bone.

show abstract

Surveillance for lung metastasis from giant cell tumor of bone

Rosario

Kim

Yun

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group

Cited by 42 publications

References 26 publications

Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application

Heat Shock Protein 70 Expression in Giant Cell Tumor of Bone and Its Clinical Application

Treating Giant Cell Tumours with Curettage, Electrocautery, Burring, Phenol Irrigation, and Cementation

Surveillance for lung metastasis from giant cell tumor of bone

Contact Info

Product

Resources

About